WO2004048402B1 - A hepatitis c virus codon optimized non-structural ns3/4a fusion gene - Google Patents

A hepatitis c virus codon optimized non-structural ns3/4a fusion gene

Info

Publication number
WO2004048402B1
WO2004048402B1 PCT/IB2003/006361 IB0306361W WO2004048402B1 WO 2004048402 B1 WO2004048402 B1 WO 2004048402B1 IB 0306361 W IB0306361 W IB 0306361W WO 2004048402 B1 WO2004048402 B1 WO 2004048402B1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
seq
peptide
ribavirin
composition
Prior art date
Application number
PCT/IB2003/006361
Other languages
French (fr)
Other versions
WO2004048402A3 (en
WO2004048402A2 (en
Inventor
Matti Sallberg
Original Assignee
Tripep Ab
Matti Sallberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripep Ab, Matti Sallberg filed Critical Tripep Ab
Priority to ES03782748T priority Critical patent/ES2421132T3/en
Priority to EP03782748.2A priority patent/EP1567190B1/en
Priority to KR1020057009575A priority patent/KR101144642B1/en
Priority to JP2004554859A priority patent/JP4660195B2/en
Priority to CA 2506820 priority patent/CA2506820A1/en
Priority to AU2003290385A priority patent/AU2003290385B2/en
Publication of WO2004048402A2 publication Critical patent/WO2004048402A2/en
Publication of WO2004048402A3 publication Critical patent/WO2004048402A3/en
Publication of WO2004048402B1 publication Critical patent/WO2004048402B1/en
Priority to HK06102404A priority patent/HK1081973A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Aspects of the present invention relate to the creation of a codon-optimized hepatitis C virus (HCV) NS3/4A gene. Embodiments include said NS3/4A gene, fragments of said gene, HCV peptides encoded by said nucleic acids, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.

Claims

AMENDED CLAIMS[received by the International Bureau on 28 July 2004 (28.07.04); original claims 1-36 replaced by new claims 1-39 (3 pages) ]WHAT IS CLAIMED IS:
1. A purified or isolated nucleic acid comprising at least 30 consecutive nucleotides of the sequence of SEQ ID NO:35 or the complement thereof.
2. The purified or isolated nucleic acid of claim 1, wherein said nucleic acid comprises the sequence of SEQ ID NO:35.
3. The purified or isolated nucleic acid of claim 1, wherein said nucleic acid consists of the sequence of SEQ ID NO:35.
4. The nucleic acid of claim 1, comprising at least 50 consecutive nucleotides.
5. The nucleic acid of claim 1, comprising at least 100 consecutive nucleotides.
6. The nucleic acid of claim 1, comprising at least 200 consecutive nucleotides.
7. The nucleic acid of claim 1, comprising at least 500 consecutive nucleotides.
8. A purified or isolated nucleic acid encoding the amino acid sequence of SEQ ID NO:36.
9. A vector comprising the nucleic acid of claim 1.
10. A cell comprising the nucleic acid of claim 1.
11. A purified or isolated peptide comprising at least 30 consecutive amino acids of the sequence of SEQ ID NO:36.
12. A purified or isolated peptide comprising the amino acid sequence of SEQ ID NO:36.
13. A purified or isolated peptide consisting of the amino acid sequence of SEQ ID NO:36.
14. The peptide of claim 12 comprising at least 35 consecutive amino acids.
15. The peptide of claim 12 comprising at least 40 consecutive amino acids.
16. The peptide of claim 12 comprising at least 45 consecutive amino acids.
17. The peptide of claim 12 comprising at least 50 consecutive amino acids.
18. A pharmaceutical composition comprising the nucleic acid of claim 1, 2, 3, 4, 5, 6, 7 or 8 and a pharmaceutically acceptable carrier.
19. The pharmaceutical composition of claim 18, further comprising an adjuvant.
20. The pharmaceutical composition of claim 19, wherein said adjuvant is ribavirin.
21. A pharmaceutical composition comprising any one of the peptides of claims 11, 12, 13, 14, 15, 16 or 17.
22. The pharmaceutical composition of claim 21, further comprising an adjuvant.
23. The pharmaceutical composition of claim 22, wherein said adjuvant is ribavirin.
24. A method of making an immunogen preparation comprising: providing ribavirin; providing the nucleic acid of SEQ TD NO:35; and
77 combining said ribavirin and said nucleic acid so as to formulate said immunogen preparation.
25. A method of making an immunogen preparation comprising: providing ribavirin; providing the peptide of SEQ ID NO:36; and combining said ribavirin and said peptide so as to formulate said immunogen preparation.
26. A method of making an immunogen preparation comprising: providing ribavirin; providing the nucleic acid of SEQ ID NO:35 or a fragment thereof at least 30 consecutive nucleotides in length; and combining said ribavirin and said nucleic acid so as to formulate said immunogen preparation.
27. A method of making an immunogen preparation comprising: providing ribavirin; providing the nucleic acid of SEQ TD NO:36 or a fragment thereof at least 10 consecutive amino acids in length; and combining said ribavirin and said nucleic acid so as to formulate said immunogen preparation.
28. An improved hepatitis C virus immunogen preparation, wherein the improvement comprises a nucleic acid comprising at least 30 consecutive nucleotides of the sequence of SEQ TD NO:35.
29. The immunogen preparation of claim 28, wherein said improvement comprises a nucleic acid consisting of the sequence of SEQ TD NO:35.
30. The immunogen preparation of claim 28, wherein said improvement comprises a nucleic acid comprising the sequence of SEQ TD NO:35.
31. Use of the nucleic acid of claim 1 to prepare an HCV antiviral composition.
78
32. Use of the peptide of claim 12 to prepare an HCV antiviral composition.
33. A composition comprising the nucleic acid of claim 1.
34. A composition comprising the nucleic acid of claim 2.
35. A composition comprising the nucleic acid of claim 3.
36. A composition comprising the nucleic acid of claim 8.
37. A composition comprising the peptide of claim 11.
38. A composition comprising the nucleic acid of claim 12.
39. A composition comprising the nucleic acid of claim 13.
79
PCT/IB2003/006361 2002-11-26 2003-11-25 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene WO2004048402A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES03782748T ES2421132T3 (en) 2002-11-26 2003-11-25 A non-structural NS3 / 4A fusion gene optimized for hepatitis C virus codon
EP03782748.2A EP1567190B1 (en) 2002-11-26 2003-11-25 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
KR1020057009575A KR101144642B1 (en) 2002-11-26 2003-11-25 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
JP2004554859A JP4660195B2 (en) 2002-11-26 2003-11-25 Hepatitis C virus codon optimized nonstructural NS3 / 4A fusion gene
CA 2506820 CA2506820A1 (en) 2002-11-26 2003-11-25 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
AU2003290385A AU2003290385B2 (en) 2002-11-26 2003-11-25 A hepatitis C virus codon optimized non-structural NS3/4A fusion gene
HK06102404A HK1081973A1 (en) 2002-11-26 2006-02-23 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/307,047 2002-11-26
US10/307,047 US7022830B2 (en) 2000-08-17 2002-11-26 Hepatitis C virus codon optimized non-structural NS3/4A fusion gene

Publications (3)

Publication Number Publication Date
WO2004048402A2 WO2004048402A2 (en) 2004-06-10
WO2004048402A3 WO2004048402A3 (en) 2004-07-29
WO2004048402B1 true WO2004048402B1 (en) 2004-10-07

Family

ID=32392514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/006361 WO2004048402A2 (en) 2002-11-26 2003-11-25 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene

Country Status (10)

Country Link
US (9) US7022830B2 (en)
EP (1) EP1567190B1 (en)
JP (1) JP4660195B2 (en)
KR (1) KR101144642B1 (en)
CN (1) CN100566753C (en)
AU (1) AU2003290385B2 (en)
CA (1) CA2506820A1 (en)
ES (1) ES2421132T3 (en)
HK (1) HK1081973A1 (en)
WO (1) WO2004048402A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP1567547A2 (en) * 2002-11-26 2005-08-31 Tripep Ab Hepatisis c virus nonstructural protein 4a (ns4a) is an enhancer element
US7785875B2 (en) * 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
WO2008004992A2 (en) * 2005-05-25 2008-01-10 Tripep Ab Transdermal formulations containing hepatitis c virus immunogens and an ethoxylated oil
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
RU2431499C2 (en) * 2005-10-07 2011-10-20 Пройекто Де Биомедисина Сима, С.Л. Immunostimulating combination for prevention and treatment of hepatitis c
BRPI0617330A2 (en) * 2005-10-13 2011-07-19 Virexx Medical Corp chimeric hepatitis c virus polypeptide antigen and fc fragment to arouse an immune response
ATE556136T1 (en) * 2006-03-09 2012-05-15 Transgene Sa NON-STRUCTURAL HCV FUSION PROTEIN
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
WO2009022236A2 (en) * 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
US8445663B2 (en) 2009-02-02 2013-05-21 Chrontech Pharma Ab Compositions and methods that enhance an immune response
IN2012DN02333A (en) * 2009-10-16 2015-08-21 Dow Agrosciences Llc
CA2784488A1 (en) 2009-12-16 2011-06-23 Chrontech Pharma Ab Injection needle and device
US20120027795A1 (en) * 2010-05-11 2012-02-02 Matti Sallberg Simple vaccines from dna launched suicidal flaviviruses
CA2839196A1 (en) 2011-06-15 2012-12-20 Chrontech Pharma Ab Injection needle and device
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2014064534A2 (en) * 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
AU2017332854A1 (en) 2016-09-21 2019-04-11 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
CN117089575B (en) * 2023-10-20 2024-02-20 浙江迪福润丝生物科技有限公司 Method for screening plasmid and HCV protease inhibitor and evaluating drug effect

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468A (en) * 1837-11-20 Thomas french
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4486630A (en) * 1983-03-11 1984-12-04 Fetchko John E Device for use by quadri-plegics to operate a computer, video game or the like by the use of movements of the jaw and eyebrows
US4818540A (en) 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2758184B2 (en) 1987-06-22 1998-05-28 メデバ ホールディングス ベスローテン ベノートスハップ Hepatitis B surface antigen vaccine
US5968775A (en) * 1987-11-18 1999-10-19 Chiron Corporation Hepatitis C virus infected cell systems
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US6171782B1 (en) * 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5679342A (en) * 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
CN1049686C (en) 1987-11-18 2000-02-23 希龙股份有限公司 Nanbv diagnostics and vaccines
US4950647A (en) * 1988-10-04 1990-08-21 Nucleic Acid Research Institute T cell immunopotentiator
HUT54896A (en) 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
DE69033891T2 (en) 1989-05-18 2002-08-29 Chiron Corp NANBV diagnostics: polynucleotides, suitable for screening for hepatitis C virus
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE69031791T2 (en) 1989-08-25 1998-04-02 Chiron Corp Process for HCV cultivation in cell lines from B or T lymphocytes
JP3156200B2 (en) 1989-09-15 2001-04-16 国立予防衛生研究所長 New HCV isolate
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
PL169273B1 (en) * 1990-04-04 1996-06-28 Chiron Corp Method of testing chemical compounds for their activity against hepatitis c
UA41266C2 (en) 1990-04-04 2001-09-17 Чірон Корпорейшн COMBINATION OF HEPATITIS C VIRUS (HCV) EPITOPE SEQUENCES, METHOD OF DETECTION OF ANTIBODIES TO HEPATITIS VIRUS (HCV), KIT FOR ANALYTES ANALYTES ANALYSIS ANALYSIS
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5747339A (en) * 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
EP0543924B1 (en) 1990-08-10 1997-06-18 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
CA2027434C (en) 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5710008B1 (en) 1990-10-12 1999-09-07 Spectral Diagnostics Inc Method and device for diagnosing and distinguishing chest pain in early onset thereof
RO115446B1 (en) 1990-11-08 2000-02-28 Chiron Corp Process for producing purified asialoglycoproteins from hepatitis c virus
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
EP0491077A1 (en) 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
US6190864B1 (en) * 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
DK0585398T3 (en) 1991-05-08 2004-02-02 Chiron Corp HCV genomic sequences for diagnostic and therapeutic agents
FR2677372B1 (en) 1991-06-06 1994-11-10 Pasteur Institut NUCLEOTIDE AND PEPTIDE SEQUENCES OF A HEPATITIS C VIRUS ISOLATE, DIAGNOSTIC AND THERAPEUTIC APPLICATIONS.
RO117329B1 (en) * 1991-06-24 2002-01-30 Chiron Corp Emeryville Polypeptides containing a hcv sequence
PL171489B1 (en) * 1991-09-13 1997-05-30 Chiron Corp Method of obtaining an immunogenous composition capable to immunologically cross-react with many hcv isolates
US5290676A (en) * 1991-09-24 1994-03-01 Fuji Photo Film Co., Ltd. Silver halide photographic light-sensitive material
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
IL108449A (en) 1993-01-26 2011-09-27 Weiner David B Use of a polynucleotide function enhancer and a nucleic acid molecule to manufacture a pharmaceutical composition for introducing genetic material into cells
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US7255997B1 (en) * 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
DE69435023T2 (en) * 1993-04-27 2008-09-11 N.V. Innogenetics S.A. SEQUENCES OF THE GENOTYPE OF HEPATITIS C-VIRUS AND THEIR USE AS MEDICAMENTS AND DIAGNOSTICS
EP0992580B1 (en) * 1993-11-04 2005-03-09 Innogenetics N.V. Immunodominant human T-cell epitopes of Hepatitis C virus
IT1272179B (en) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLITHIC ACTIVITY OF THE NS3 PROTEASE OF THE VIRUS HCV.
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
JP3365635B2 (en) 1994-09-23 2003-01-14 ゾナジェン，インコーポレイテッド Chitosan-induced immune enhancement
US6235888B1 (en) * 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
WO1996013590A2 (en) * 1994-10-21 1996-05-09 Innogenetics N.V. New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
FR2730935A1 (en) * 1994-12-21 1996-08-30 Vacsyn Sa VACCINE WITH INCREASED IMMUNOGENICITY
US5932556A (en) * 1995-09-17 1999-08-03 Tam; Robert C Methods and compositions for regulation of CD28 expression
WO1996028162A1 (en) 1995-03-14 1996-09-19 University Of Medicine & Dentistry Of New Jersey New drug combination for the treatment of viral diseases
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US5843752A (en) 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
US5712154A (en) * 1995-06-07 1998-01-27 W.R. Grace & Co.-Conn. Dual fiber bioreactor
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
SI9720013A (en) 1996-01-23 1999-06-30 Icn Pharmaceuticals, Inc. Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated T-lymphocytes
US6150337A (en) * 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US6514731B1 (en) * 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
WO1997047358A1 (en) 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US6518014B1 (en) 1996-07-11 2003-02-11 Bristol-Myers Squibb Company Hepadnavirus cores
JP2001500738A (en) * 1996-09-17 2001-01-23 カイロン コーポレイション Compositions and methods for treating intracellular diseases
EP0969863A4 (en) 1996-09-18 2001-11-07 Univ Texas Viral defective interfering particles and uses thereof
UA63915C2 (en) 1996-10-16 2004-02-16 Ай-Сі-Ен Фармасьютикалз, Інк. Monocyclic l-nucleosides, analogues and use thereof
EP0961775B1 (en) 1996-10-16 2004-07-14 ICN Pharmaceuticals, Inc. Purine l-nucleosides, analogs and uses thereof
IL119833A (en) * 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
YU61598A (en) 1997-01-17 2003-02-28 Icn Pharmaceuticals Inc. Cytokine related treatments of disease
CA2280195A1 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
WO1998037180A2 (en) 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
DE19720341C1 (en) * 1997-05-15 1998-08-27 Clariant Gmbh 3,5-Di:fluoro-aniline preparation in good yield
US6153421A (en) 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
US6183121B1 (en) * 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
AU1108799A (en) * 1997-10-20 1999-05-10 Gtc Biotherapeutics, Inc. Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
AU1416099A (en) 1997-11-28 1999-06-16 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
NZ506245A (en) 1998-02-12 2003-08-29 Immune Complex Corp Strategically modified hepatitis b core proteins and their derivatives
JP2002512370A (en) 1998-04-17 2002-04-23 イノジェネティックス・ナムローゼ・フェンノートシャップ Improved immunodiagnostic assay using reducing agents
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
IL144130A0 (en) 1999-01-29 2002-05-23 Icn Pharmaceuticals Modulation of immune response by ribavirin
US20020187945A1 (en) * 1999-01-29 2002-12-12 Robert Tam Modulation of immune response by ribavirin
US6214853B1 (en) * 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
DE60016765T2 (en) * 1999-08-25 2005-11-24 Merck & Co., Inc. SYNTHETIC PAPILLOMA GENES WHICH ARE OPTIMIZED FOR EXPRESSION IN HUMAN CELLS
CN101684146A (en) 1999-11-24 2010-03-31 诺华疫苗和诊断公司 Novel hcv non-structural polypeptide
US7001760B2 (en) 2000-04-20 2006-02-21 Wang-Schick Ryu Hepatitis B virus vectors for gene therapy
EP1350105B1 (en) 2000-06-15 2007-07-25 Novartis Vaccines and Diagnostics, Inc. Immunoassays for anti-hcv antibodies
US6670152B1 (en) * 2000-06-29 2003-12-30 Wisconsin Alumni Research Foundation Enzymatic reduction of cobalt in cobalamin
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
RU2286172C2 (en) 2000-08-17 2006-10-27 Трипеп Аб Ribavirin-containing vaccines and methods for their application
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP1947185B1 (en) 2000-08-17 2011-07-20 Tripep Ab HCV NS3/4A encoding nucleic acid
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US20040101957A1 (en) 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
DK1436397T3 (en) * 2001-10-11 2010-08-09 Merck Sharp & Dohme Hepatitis C virus vaccine
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7307006B2 (en) * 2005-02-28 2007-12-11 Semiconductor Energy Laboratory Co., Ltd. Method of manufacturing semiconductor device
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
WO2009022236A2 (en) * 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform

Also Published As

Publication number Publication date
HK1081973A1 (en) 2006-05-26
US7307066B2 (en) 2007-12-11
US8158602B2 (en) 2012-04-17
KR101144642B1 (en) 2012-05-11
EP1567190B1 (en) 2013-04-10
US7943149B2 (en) 2011-05-17
AU2003290385A1 (en) 2004-06-18
US20080213290A1 (en) 2008-09-04
CN100566753C (en) 2009-12-09
US20050124573A1 (en) 2005-06-09
JP4660195B2 (en) 2011-03-30
US20100104592A1 (en) 2010-04-29
WO2004048402A3 (en) 2004-07-29
CA2506820A1 (en) 2004-06-10
EP1567190A2 (en) 2005-08-31
US20110081381A1 (en) 2011-04-07
JP2006523434A (en) 2006-10-19
AU2003290385B2 (en) 2009-11-19
US20030206919A1 (en) 2003-11-06
US8163712B2 (en) 2012-04-24
US20110082287A1 (en) 2011-04-07
KR20050085175A (en) 2005-08-29
US20110065174A1 (en) 2011-03-17
US7223743B2 (en) 2007-05-29
US20060183705A1 (en) 2006-08-17
CN1741817A (en) 2006-03-01
US8163547B2 (en) 2012-04-24
US7638499B2 (en) 2009-12-29
ES2421132T3 (en) 2013-08-29
US20120208870A1 (en) 2012-08-16
US7022830B2 (en) 2006-04-04
WO2004048402A2 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
WO2004048402B1 (en) A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
Bishop et al. The complete sequence and coding content of snowshoe hare bunyavirus small (S) viral RNA species
Muerhoff et al. Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis
KR920007439B1 (en) Hybrid human leukocyte interferons
WO1996004385A3 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
JP2003530839A5 (en)
SA03240005B1 (en) Hepatitis C inhibitor tri-peptices
CA2389206A1 (en) Activation of hcv-specific t cells
EP0746333A1 (en) Method for reproducing in vitro the proteolytic activity of the ns3 protease of hepatitis c virus (hcv)
CA2418199A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
US7854937B2 (en) Flavivirus fusion inhibitors
Hayashi et al. Molecular cloning and heterogeneity of the human hepatitis C virus (HCV) genome
AU3406595A (en) Nucleotide and amino acid sequences of the envelope 1 and core genes of hepatitis c virus
JP2004531242A5 (en)
US5714371A (en) Method for refolding insoluble aggregates of hepatitis C virus protease
Keese et al. Nucleotide sequence of the genome of an Australian isolate of turnip yellow mosaic tymovirus
WO2003051912A3 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
HU196846B (en) Process for producing biologically active derivatives of human gamma-interferon and pharmaceutical compositions comprising the same
HK1130664A1 (en) Hepatitis c virus non structural fusion protein
CN102112601B (en) New fusion rotein and the purposes for the preparation of the vaccine for hepatitis C thereof
JPH0195791A (en) Novel polypeptide,its manufacturing method,vector therefor and drug containing the same
Naoyuki et al. Use of the deoxyinosine-containing probe to isolate and sequence cDNA encoding the fusion (F) glycoprotein of Sendai virus (HVJ)
US5026686A (en) Antiviral peptides
Takahashi et al. Nucleotide sequence of the capsid protein gene of bean yellow mosaic virus chlorotic spot strain
EP0240224A2 (en) An alpha interferon analogue

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20040728

WWE Wipo information: entry into national phase

Ref document number: 2506820

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020057009575

Country of ref document: KR

Ref document number: 2004554859

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003290385

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003782748

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038A92087

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057009575

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003782748

Country of ref document: EP